Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Inclusion Criteria:

• Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

  • Recurrent or persistent disease

• At least 1 unidimensionally measurable target lesion

  • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • Tumors within a previously irradiated field considered nontarget lesions

• At least one prior platinum-based chemotherapy regimen (containing carboplatin, cisplatin, or another organoplatinum compound) for primary disease required

  • Initial treatment may include high-dose, consolidation, or extended therapy
  • Initial treatment-free interval less than 12 months for patients who received only 1 prior platinum-based regimen
  • Initial treatment-free interval of more than 12 months allowed provided disease progression has occurred within 12 months after retreatment with a second-line platinum-based regimen
• Ineligible for a higher priority GOG protocol (e.g., any active phase III GOG protocol for the same patient population)
• Performance status - GOG 0-2 (if patient has received one prior treatment regimen)
• Performance status - GOG 0-1 (if patient has received two prior treatment regimens)
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT/SGPT no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2.5 times ULN
• Creatinine no greater than 1.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 3 months after study participation
• No active infection requiring antibiotics
• No greater than grade 1 sensory and motor neuropathy
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No signs or symptoms of bowel dysfunction
• At least 3 weeks since prior immunologic therapy directed at the malignant tumor
• No concurrent biologic therapy or immunotherapy for the malignant tumor
• Recovered from prior chemotherapy
• No prior noncytotoxic chemotherapy for persistent or recurrent disease
• One additional cytotoxic regimen for persistent or recurrent disease allowed
• No concurrent chemotherapy for the malignant tumor
• At least 1 week since prior hormonal therapy directed at the malignant tumor
• No concurrent therapeutic corticosteroids
• No concurrent anticancer hormonal therapy
• Concurrent hormone replacement therapy allowed
• Recovered from prior radiotherapy
• No prior radiotherapy to more than 25% of marrow-bearing areas
• No concurrent anticancer radiotherapy
• Recovered from recent prior surgery
• At least 3 weeks since other prior therapies directed at the malignant tumor
• No prior imatinib mesylate
• No prior anticancer therapy that would preclude study participation
• No concurrent therapeutic anticoagulation with warfarin
• No other concurrent investigational drugs
• No concurrent amifostine or other protective reagents